Hepatic very-low-density lipoprotein synthesis enzymes and regulators

The term "Hepatic VLDL synthesis enzymes/regulators" refers collectively to the group of enzymes, regulatory proteins, and co-factors responsible for the biosynthesis, assembly, and secretion of very-low-density lipoproteins (VLDL) in the liver. Key components include **apolipoprotein B-100 (APOB)** (essential structural protein for VLDL), **microsomal triglyceride transfer protein (MTP)** (mediates lipidation and VLDL formation), as well as elongases, desaturases, and other enzymes involved in fatty acid and triglyceride synthesis. The regulation of VLDL synthesis is complex and closely tied to hepatic lipid metabolism, energy state, and dietary factors. Dysregulation is linked to disorders such as atherosclerosis, fatty liver disease, insulin resistance, and other metabolic diseases. Some drugs have been developed to specifically inhibit components like APOB or MTP to reduce circulating VLDL and lower cardiovascular risk[1][3]. Note: This entry is not a single canonical molecular target, but a broad functional class encompassing multiple related molecular entities and regulatory processes in hepatic lipid metabolism. This makes it less precise or actionable as an individual therapeutic target[1][2][3].

Inhibition of apolipoprotein B (APOB) synthesis (prevents VLDL assembly and secretion) Inhibition of microsomal triglyceride transfer protein (MTP) (blocks lipidation of APOB and VLDL formation)